MA67594B1 - Composition aqueuse - Google Patents

Composition aqueuse

Info

Publication number
MA67594B1
MA67594B1 MA67594A MA67594A MA67594B1 MA 67594 B1 MA67594 B1 MA 67594B1 MA 67594 A MA67594 A MA 67594A MA 67594 A MA67594 A MA 67594A MA 67594 B1 MA67594 B1 MA 67594B1
Authority
MA
Morocco
Prior art keywords
aqueous composition
vessel
ester
acceptable salt
pharmacologically acceptable
Prior art date
Application number
MA67594A
Other languages
English (en)
French (fr)
Other versions
MA67594A1 (fr
Inventor
Rika ORITANI
Chise KITANI
Akinori Nishimoto
Original Assignee
Tsubota Laboratory, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsubota Laboratory, Inc. filed Critical Tsubota Laboratory, Inc.
Publication of MA67594A1 publication Critical patent/MA67594A1/fr
Publication of MA67594B1 publication Critical patent/MA67594B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MA67594A 2022-03-25 2023-03-24 Composition aqueuse MA67594B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022050275 2022-03-25
PCT/JP2023/011739 WO2023182480A1 (ja) 2022-03-25 2023-03-24 水性組成物

Publications (2)

Publication Number Publication Date
MA67594A1 MA67594A1 (fr) 2025-07-31
MA67594B1 true MA67594B1 (fr) 2026-01-30

Family

ID=88101709

Family Applications (1)

Application Number Title Priority Date Filing Date
MA67594A MA67594B1 (fr) 2022-03-25 2023-03-24 Composition aqueuse

Country Status (14)

Country Link
US (1) US20250213510A1 (https=)
EP (1) EP4483867A1 (https=)
JP (1) JPWO2023182480A1 (https=)
KR (1) KR20240159636A (https=)
CN (1) CN118973561A (https=)
AU (1) AU2023240729A1 (https=)
CA (1) CA3254664A1 (https=)
CL (1) CL2024002831A1 (https=)
IL (1) IL315871A (https=)
MA (1) MA67594B1 (https=)
MX (1) MX2024011634A (https=)
PE (1) PE20250746A1 (https=)
TW (1) TW202400133A (https=)
WO (1) WO2023182480A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005330271A (ja) * 2004-04-20 2005-12-02 Taisho Pharmaceut Co Ltd 点眼用液剤
JP2013525451A (ja) * 2010-04-28 2013-06-20 ザ・チャイニーズ・ユニバーシティ・オブ・ホンコン 高眼圧症及び緑内障を予防及び治療する方法及び薬物
JP2016065095A (ja) * 2008-05-30 2016-04-28 参天製薬株式会社 高眼圧症及び緑内障を治療するための方法及び組成物
WO2018164113A1 (ja) * 2017-03-06 2018-09-13 学校法人 慶應義塾 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
WO2018181294A1 (ja) * 2017-03-27 2018-10-04 興和株式会社 医薬製剤
WO2020129965A1 (ja) * 2018-12-18 2020-06-25 参天製薬株式会社 ４－フェニル酪酸を含有する老視の治療または予防剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
JP2009078977A (ja) * 2007-09-25 2009-04-16 Japan Health Science Foundation 心筋の小胞体ストレス抑制剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005330271A (ja) * 2004-04-20 2005-12-02 Taisho Pharmaceut Co Ltd 点眼用液剤
JP2016065095A (ja) * 2008-05-30 2016-04-28 参天製薬株式会社 高眼圧症及び緑内障を治療するための方法及び組成物
JP2013525451A (ja) * 2010-04-28 2013-06-20 ザ・チャイニーズ・ユニバーシティ・オブ・ホンコン 高眼圧症及び緑内障を予防及び治療する方法及び薬物
WO2018164113A1 (ja) * 2017-03-06 2018-09-13 学校法人 慶應義塾 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
WO2018181294A1 (ja) * 2017-03-27 2018-10-04 興和株式会社 医薬製剤
WO2020129965A1 (ja) * 2018-12-18 2020-06-25 参天製薬株式会社 ４－フェニル酪酸を含有する老視の治療または予防剤

Also Published As

Publication number Publication date
TW202400133A (zh) 2024-01-01
US20250213510A1 (en) 2025-07-03
CN118973561A (zh) 2024-11-15
IL315871A (en) 2024-11-01
CA3254664A1 (en) 2025-07-03
PE20250746A1 (es) 2025-03-13
MA67594A1 (fr) 2025-07-31
CL2024002831A1 (es) 2025-01-24
JPWO2023182480A1 (https=) 2023-09-28
WO2023182480A1 (ja) 2023-09-28
EP4483867A1 (en) 2025-01-01
AU2023240729A1 (en) 2024-10-03
KR20240159636A (ko) 2024-11-05
MX2024011634A (es) 2024-09-30

Similar Documents

Publication Publication Date Title
Brill et al. The passage of tissue fluid into the clinically healthy gingival pocket
Winum et al. Therapeutic potential of sulfamides as enzyme inhibitors
Otto et al. Cysteine proteases and their inhibitors
Bescond et al. Influence of homocysteine on matrix metalloproteinase-2: activation and activity
Winum et al. The sulfamide motif in the design of enzyme inhibitors
FR2424311A1 (fr) Compositions de nettoyage pour des lentilles de contact, a base d'uree ou d'un sel d'acide avec la guanidine, et d'un reducteur
MA67594B1 (fr) Composition aqueuse
JP2011517318A5 (https=)
BR0308400A (pt) Composições beneficiadas redutoras de água
FR2356600A1 (fr) Agent germicide pour systemes aqueux a base de peroxyde d'hydrogene et son utilisation
BE1003188A4 (fr) Composition pharmaceutique destinee a etre administree par voie orale et contenant de la n-acetyl-cysteine, et son application.
BE899779A (fr) Composition detergente liquide a une seule phase, stabilisee, chargee d'adjuvant de detergence et contenant des enzymes.
WO2019144692A1 (zh) 一种胰高血糖素保护剂及其应用
CN104059794A (zh) 一种分析仪的清洗液
GB863739A (en) Diagnostic preparation for the determination of serum alkaline phosphatase
Stauber et al. Fluorescence demonstration of cathepsin B activity in skeletal, cardiac, and vascular smooth muscle.
FR2980974A1 (fr) Composition comprenant un sel d'hypothiocyanite d'un cation alcalin, a l'etat solide
FR3131693B1 (fr) Composition pour le traitement de fibres kératineuses, comprenant un silicate soluble dans l'eau et un acide soluble dans l'eau
FR2365340A1 (fr) Composition pharmaceutique contenant des phenylglycines l ou dl (racemiques)
FR3123563B1 (fr) Utilisation de l’amitriptyline et/ou l’un de ses sels pharmaceutiquement acceptable comme agent conservateur
Ojala Interpreting Late Bronze Age Uppland: Regional identity and interregional contacts
US740855A (en) Mercurous chlorid.
FR517830A (fr) Procédé pour la fabrication anodique de solutions ou de corps solides renfermant de l'oxygène actif
FR3089419B1 (fr) Composition de matière nettoyante
JPS5678624A (en) Concretion preventing agent of granulated slag